BofA analyst Geoff Meacham lowered the firm’s price target on Moderna to $110 from $125 and keeps a Neutral rating on the shares following a “mixed” Q3 print. With Moderna creating a financial framework looking to 2025 that highlighted a lack of top-line growth, the firm has “modestly adjusted” its P&L and revenue forecasts, the analyst tells investors in a post-earnings note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRNA: